New International League of Associations for Rheumatology (ILAR) recommendations are now available for the treatment of patients with psoriatic arthritis living in resource-poor regions, including Central and South America and Africa.
New International League of Associations for Rheumatology (ILAR) recommendations are now available for the treatment of patients with psoriatic arthritis (PsA) living in resource-poor regions, including Central and South America and Africa.
The new ILAR recommendations were adapted from existing PsA treatment recommendations developed by the European League Against Rheumatism (EULAR)1 and the Group for Research and Assessment of Psoriasis and PSA (GRAPPA),2 as well as expert opinion from these regions. EULAR and GRAPPA issued their respective recommendations for management of PsA in 2015, but there have been concerns that the guidelines were primarily based on studies conducted in resource-wealthy countries and thus might not be applicable to resource-poor countries. The study, by Musaab Elmamoun, MBBS, MRCPI, and a group of international expert colleagues, was presented at the annual European Congress of Rheumatology, held June 13-16, 2018, in Amsterdam, and hosted by EULAR.
The first part of the collaborative process was undertaken to assess and adapt EULAR and GRAPPA treatment recommendations for PsA to cover patients living in Central and South America and Africa:
The adaptation process resulted in the creation of 5 principles for the management of PsA that address goals of therapy, assessment of domains, assessment of relevant comorbidities, safety of pharmacotherapy and shared decision-making, and frequency of follow up.
Finally, the collaborative group developed the following 6 recommendations for the management of PsA:
References
Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment
May 4th 2024A review article summarizes the product attributes of reference and biosimilar adalimumab products, such as formulation with or without citrate, delivery volume, and needle gauge, relevant to patients’ experience of injection-site pain.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.